home · filing · 0000950170-24-110462
8-K filed October 1, 2024, 7:59 PM ET
ticker TRVI
CIK 0001563880
leadership
confidence high
sentiment neutral
materiality 0.45
Trevi Therapeutics names James Cassella Chief Development Officer; CMO David Clark departs
Trevi Therapeutics, Inc.
James Cassella appointed CDO effective Sept 30, 2024; he resigned from the Board on that date.
David Clark stepped down as CMO effective Sept 27, 2024, to care for a family member; will consult at $400/hour.
Cassella has 35+ years CNS drug development experience, including CDO at Concert Pharmaceuticals and FDA approval of Leqselvi.
Company is advancing Haduvio for IPF cough and refractory chronic cough; pivotal program and regulatory submission planned.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-09-27
Filed October 1, 2024, 7:59 PM ET
David Clark, MBChB, MRCP, had stepped down as the Company’s Chief Medical Officer, effective as of September 27, 2024.
Effective 2024-09-30
Filed October 1, 2024, 7:59 PM ET
Dr. Cassella resigned from his position as a member of the Board of Directors of the Company, effective as of September 30, 2024.
Effective 2024-09-30
Filed October 1, 2024, 7:59 PM ET
announced that James Cassella, Ph.D., had agreed to join the Company as its Chief Development Officer.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Clark departed as Chief Medical Officer at Trevi Therapeutics, Inc..
Action stepped down
Role Chief Medical Officer
Exact text from the filing
David Clark, MBChB, MRCP, had stepped down as the Company’s Chief Medical Officer, effective as of September 27, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
James Cassella resigned as Member of the Board of Directors at Trevi Therapeutics, Inc..
Action resigned
Role Member of the Board of Directors
Exact text from the filing
Dr. Cassella resigned from his position as a member of the Board of Directors of the Company, effective as of September 30, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
James Cassella was appointed as Chief Development Officer at Trevi Therapeutics, Inc..
Action appointed
Role Chief Development Officer
Exact text from the filing
announced that James Cassella, Ph.D., had agreed to join the Company as its Chief Development Officer.
View on SEC.gov
Source: SEC EDGAR
accession 0000950170-24-110462
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.